Company: VRCA
Filing Date: 2025-04-30
Form Type: DEFR14A
Source: 0001193125-25-105562
Chunk: 57

Company: Verrica Pharmaceuticals Inc.
Filing Date: 2025-04-30
Form: DEFR14A
Chunk 57
---
 reason, in either case within 12 months following or 1 month prior to the effective date of a change in control, then Mr. Hayes would be entitled to the following severance benefits, less applicable tax withholding:

| • |     | payment of his then-current base salary in accordance with normal payroll procedures for 12 months; |

| • |     | payment of a cash severance benefit equal to Mr. Hayes’s annual bonus at the target percentage for the year in which the termination occurs; |

| • |     | payment or reimbursement of continued health coverage for Mr. Hayes and his dependents under COBRA for 12 months; and |

| • |     | all equity awards held by Mr. Hayes will automatically vest. |

**Dr. Goldenberg In connection with his resignation from employment as our Chief Medical Officer, on February 27, 2025, we entered into a Release Agreement with Dr. Goldenberg effective as of March 3, 2025, which contains (i) a release of claims against us and (ii) the following separation benefits: (a) payment of his then current base salary in accordance with normal payroll procedures for six months and (b) if elected, payment of continued health coverage for Dr. Goldenberg and his dependents under COBRA for up to 12 months. We also entered into a Consulting Agreement with Dr. Goldenberg, pursuant to which Dr. Goldenberg will provide consulting services to us from time to time. Notwithstanding such service under the Consulting Agreement, the equity awards he held ceased to vest as of March 3, 2025. 40

Mr. White

In connection with his resignation from employment as our President and Chief Executive Officer, on November 4, 2024, we entered into a Release Agreement with Mr. White effective as of November 5, 2024, which contains (i) a release of claims against us and (ii) the following separation benefits: (a) payment of his current base salary in accordance with normal payroll procedures for 12 months and (b) if elected, payment of continued health coverage for Mr. White and his dependents under COBRA for up to 12 months.

Mr. Bonaccorso

In connection with his resignation from employment as our Chief Commercial Officer, on August 30, 2024, we entered into a Release Agreement with Mr. Bonaccorso, which contains (i) a release of claims against us and (ii) the following separation